Thu Sep 12 08:21:00 UTC 2024: ## PIONeeR Project to Present Late-Breaking Results at ESMO Congress 2024
**Barcelona, Spain (Sept. 12, 2024)** – The PIONeeR Project, a collaborative effort spanning multiple research institutions and hospitals across three countries, will present groundbreaking results from its Phase Ib/IIa clinical trial at the upcoming ESMO Congress 2024. This umbrella study explores ways to overcome resistance to immunotherapy in advanced non-small cell lung cancer (NSCLC).
The presentation, led by Principal Investigator Pr Pascale Tomasini, will take place during the Presidential Symposium III: Eyes to the future, highlighting the trial’s significant contributions to the fight against cancer.
“The PIONeeR trial is a testament to collaborative research, bringing together expertise and resources to address a critical challenge in cancer treatment,” said Prof. Fabrice Barlesi, coordinator of the PIONeeR Project. “We are deeply grateful to our patients, who have played a vital role in advancing our understanding of resistance to immunotherapy.”
The project has recruited over 450 patients for its biomarker program and 114 patients for the clinical trial, which is now complete. The team is currently analyzing extensive biomarker data, aiming to uncover insights into how to overcome resistance and improve treatment outcomes for NSCLC patients.
The PIONeeR Project, funded by the French National Research Agency (ANR), brings together over 100 scientists from eight research labs and 16 hospitals, including prestigious institutions like Gustave Roussy Institute and Marseille Immunopôle. The consortium also includes industry partners such as AstraZeneca, ImCheck Therapeutics, Innate Pharma, and Veracyte.
The presentation at ESMO Congress 2024 promises to shed light on the PIONeeR Project’s advancements in understanding and combating immunotherapy resistance, potentially leading to new treatment strategies and improved outcomes for NSCLC patients.
First Piper 